Health Care & Life Sciences » Pharmaceuticals | Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.32
Market Cap
$27.67 M
Shares Outstanding
54.26 M
Public Float
53 M

Profile

Address
480 Arsenal Street
Watertown Massachusetts 02472
United States
Employees -
Website http://www.tphase.com
Updated 07/08/2019
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

Financials

View All
Created with Highcharts 5.0.14Tetraphase Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.29 63629 63666 74266 74283 18983 18977 48077 480114 752114 75272 15872 158201320142015201620172018025k50k75k100k125k
Created with Highcharts 5.0.14Tetraphase Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.10 48610 4869 0989 09811 68611 6865 1455 1459 6669 66618 90418 90420132014201520162017201805k10k15k20k

Guy MacDonald
President, Chief Executive Officer & Director
L. Patrick Gage
Chairman